Abstract: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic.

Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.

Abstract: The present invention provides a microarray having one or more fusion proteins non-covalently attached to a solid support. Non-covalent attachment is achieved by designing a fusion protein having a polyanionic domain attached to a subject protein, and attaching the fusion protein to a solid support having a polycationic coating.

Abstract: The present invention provides methods for identifying evolutionarily significant polynucleotide and polypeptide sequences in human and/or non-human primates which may be associated with a physiological condition, such as enhanced resistance to HCV infection. The invention also provides methods for identifying evolutionarily significant polynucleotides with mutations that are correlated with susceptibility to diseases, such as BRCA1 exon 11. The methods employ comparison of human and non-human primate sequences using statistical methods. Sequences thus identified may be useful as host therapeutic targets and/or in screening assays.

Abstract: Coatings comprising protein resistant components and therapeutic components on medical devices are disclosed. The coatings act to down-regulate complement activation. Medical devices can be coated with these coatings to prevent side effects and improve patency.

Abstract: The present invention is a kit and method for purifying a protein of interest.

Abstract: FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are also disclosed.

Abstract: The present invention is directed to a composition consisting of a series of novel biologically active 33-mer peptides.

Abstract: The present invention describes methods of producing milligram quantities of three forms of purified Stat1 protein from recombinant DNA constructs. In addition, the Stat proteins may be isolated in their phosphorylated or nonphosphorylated forms (Tyr 701). The proteins can be produced in baculovirus infected insect cells, or E. coli. A compact domain in the amino terminus of Stat1? was isolated and found to enhance DNA binding due to its ability to interact with a neighboring Stat protein. A relatively protease-resistant recombinant truncated form of the Stat protein was isolated in 40-50 mg quantities. Purification of the Stat proteins were performed after modifying specific cysteine residues of the Stat proteins to prevent aggregation. Activated EGF-receptor partially purified from membranes by immunoprecipitation was shown to be capable of in vitro catalysis of the phosphorylation of the tyrosine residue of Stat1 known to be phosphorylated in vivo.

Abstract: The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-?B) activating pathway useful in the treatment of NF-?B related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than I?B.

Abstract: The present invention provides a simple cell-free protein synthesis method capable of affording synthesis of a protein in a high amount in a short time at a low cost. A method for cell-free protein synthesis using an extract derived from an insect cell, the method comprising removing a component which can pass through a semipermeable membrane through the semipermeable membrane while maintaining synthesis reaction, thereby to continuously synthesize a protein. Preferably, an mRNA is additionally supplied while said synthesis reaction is maintained. Further, said insect cell is preferably an established culture cell derived from Trichoplusia ni ovum cell.

Abstract: A distal tip, and associated method of producing, of a biosensor ion sensing transducer for use in detecting an analyte comprising an halogenated organic compound in an environment such as soil or an aqueous environment. Features include: a biocomponent comprising at least one enzyme for carrying out a dehalogenation of the compound; the biocomponent is immobilized to a surface of the tip; a treatment of the biocomponent for maintaining a period of enzymatic efficacy; and the biocomponent stabilized by means preferably selected from the group consisting of crosslinking a surface of the immobilized biocomponent, crosslinking a polymer layer to the biocomponent, adding a gel-hardening agent to the biocomponent, adding a stabilizing agent to the biocomponent, and modifying a component of the immobilizing means. Immobilization can be carried out by: (a) entrapment within a hydrogel; (b) entrapment within a polymeric network; (c) (micro)encapsulation; (d) covalent-bonding; and (e) adsorption.

Abstract: Compositions comprising PTH-rP peptides, combinations thereof, and multiepitope PTH-rP peptides, vectors for their delivery to antigen presenting cells, as well as methods are provided which are useful in the immunotherapy of parathyroid hormone related peptide expressing malignancies.

Abstract: The invention relates to a method for isolating from connective tissue a variety of glycosaminoglycan (GAG)-polypeptide complexes and polypeptides which are substantially free of contaminating DNA and other molecules such as viruses which may be associated with the DNA in the cell. The invention also relates to uses of GAG-peptide complexes and polypeptides substantially free of DNA either directly, or after further processing, for the treatment, protection and restoration of connective tissues in inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis in any of their multiple forms or other degenerative conditions in mammals.

Abstract: A prothrombin time reagent for determination of low molecular weight heparin in frsh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is ?-Cyclodextrin. The formulated reagent is air-dried and remains stable for at least 3 weeks at 37° C.

Abstract: This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.

Abstract: This invention provides novel human LXR? variant polypeptides and nucleic acids encoding such polypeptides. This invention also provides the therapeutic, diagnostic, and research utilities as well as the production of such polynucleotides and polypeptides. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).

Abstract: The invention of this application provides a protein polymer of 8 to 15 proteins in association, wherein each protein has the amino acid sequence of SEQ ID NO: 1, and where the protein polymer has an unfold activity on the higher-order structure of a protein and this protein polymer is useful for the development of therapeutic agents of various diseases due to the failure in the formation of the higher-order structure of a protein, and the like.

Abstract: A novel Bacillus thuringiensis strain deposited at the International Depository Authority of Health Canada in Winnipeg under accession number IDAC010201-5, its crystal gene having the sequence SEQ ID NO: 1 and crystal protein encoded by same having the sequence SEQ ID NO: 2 and uses thereof. More specifically, the present invention is concerned with a novel Bacillus thuringiensis, novel cry31 protoxin and toxin, nucleotide sequences encoding same and anti-cancer therapeutic applications for the toxin.

Abstract: Flax protein isolates are obtained in a procedure in which flax oil seeds are initially extracted to remove mucilage therefrom prior to crushing to recover the oil and produce a meal. The flax protein meal then is processed to recover a flax protein isolate therefrom.